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Abstract
Autoimmune hemolytic anemia (AIHA) is a disease that is seen in 1/10.000 people 
and characterized by forming antibodies against red blood cells and degradation 
of these red blood cells in reticuloendothelial system. Even autoimmune diseases 
can accompany, it is seen usually idiopathic. Paleness due to anemia, jaundice, 
tachycardia, darkening in urine color, hepatosplenomegaly are frequently seen 
clinical findings. Clinically normochrome and normocytic anemia, reticulocytosis, 
polychromasia in peripheral smear, spherocytes, indirect hyperbilirubinemia and 
increased lactate dehydrogenase are seen. Direct coombs test is the diagnostic 
test. Steroids are the first line drugs in treatment. The dosage and the treatment 
duration is formed according to patient’s clinical situation. The treatment is 
checked by complete blood count, reticulocyte and Coombs test. Immunosuppressor 
treatments are given to patients that don’t respond to treatment in 4-6 weeks or 
less patients who has recurrence at the time of decreasing the treatment dosage of 
corticosteroids. In few patient, that did not respond steroids, immunosuppressive 
treatments are used. Here, we present a patient, who is diagnosed with AIHA that we 
couldn’t manage remission by steroid treatment, and no response to rituxumab as an 
immunosuppressor, but treated successfully with microphenolat mofetil.
Otoimmün hemolitik anemi (OİHA), eritrosit antijenlerine karşı antikor oluşması, 
antikorla kaplanmış eritrositlerin retiküloendotelyal sistemde yıkımı ile karakterize, 
1/10,000 sıklıkta görülen bir hastalıktır. Otoimmün hastalıklar eşlik edebileceği gibi 
genelde idiyopatik olarak görülmektedir. Anemiye bağlı solukluk, sarılık, taşikardi, 
idrar renginde koyulaşma, hepatosplenomegali sık görülen klinik bulgular arasında 
yer almaktadır. Genellikle normokrom ve normositer anemi, retikülositoz, periferik 
yaymada polikromozi, sferosit, indirekt hiperbilirubinemi, laktat dehidrogenaz 
artışı görülmektedir. Direkt Coombs testi tanısal tetkiktir. Tedavide steroidler ilk 
tercihtir. Tedavinin dozu ve süresi hastanın kliniğine göre düzenlenmektedir. Tam kan 
sayımı, retikülosit ve Coombs testi ile tedavi takip edilmektedir. Dört-altı haftada 
yanıt alınamayan hastalarda veya kortikosteroid tedavisinin azaltıldığı dönemde 
tekrar nüks eden daha az olguda ise immünosüpresör tedaviler uygulanmaktadır. 
Burada, OİHA tanısı konulan ve steroid tedavisi ile remisyon sağlayamadığımız 
immünosüpresif tedavilerden rituksimab tedavisine cevap alamadığımız mikofenolat 
mofetil ile tedavi edilen gören bir olgu sunulmuştur.
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Introduction
Autoimmune hemolytic anemia (AIHA) is a 
disease that is characterized with the antibody 
production against erythrocyte antigens and 
degradation of the antibody coated erythrocytes 
by the reticuloendothelial system. The prevalence 
is 1 out of 100.000. In general, normochromic, 
normocytic anemia, indirect hyperbilirubinemia and 
hepatosplenomegaly are observed. Steroids are the 
first choice in the treatment. In the rare cases of 
unresponsiveness to the steroids, immunosuppressive 
treatments are applied. Herein, we present a case 
in which a hemolytic anemia diagnosis presents a 
steroid resistance, but immunosuppressive treatment 
was beneficial.
Case Report
A 2-year old male was brought in our hospital with 
the complaints of lassitude and paleness. Physical 
examination revealed a pale skin and jaundice, spleen 
was palpable for 3 cm and liver was impalpable. 
Urinary darkening was reported for two days pre-
hospitalization. Biochemical studies revealed the 
levels of hemoglobin: 4.8 g/dL, mean corpuscular 
volume: 103 fL, white blood cell (WBC): 8950 K/µL, 
thrombocyte: 256.000 K/µL, lactate dehydrogenase 
(LDH): 683 U/L, indirect bilirubin: 3.4 mg/dL, direct 
bilirubin: 1.2 mg/dL, direct Coombs (++++). Peripheral 
smear revealed a widespread schistocytes, dacrocytes, 
spherocytes, normoblasts and macrocytosis. Number 
of reticulocyte was 29%, and vitamin B12, folic acid 
and ferritin levels were normal. Serology analyses for 
toxoplasma, Rubella, cytomegalovirus, Herpes virus, 
hepatitis A and B, Epstein-Barr virus were consistent 
with the infection. After the patient was diagnosed 
with AIHA, prednisolone treatment was started with 
the dose 2 mg/kg/day divided in 3 doses. On day 10, 
after remission of hemoglobin to 12 g/dL, the steroid 
dose was decreased, and the patient was discharged. 
The patient was returned to the hospital 6 months after 
discharge with paleness and lassitude, hemoglobin 
was 7.6 g/dL, direct Coombs immunoglobulin G was 
(++), reticulocyte number was 3%. Peripheral smear 
was consistent with the hemolysis. Cold agglutinin (-) 
was detected. Prednisolone (2 mg/kg/day) treatment 
was started. Because the hemoglobin levels did not 
increase after 3 days of hospitalization, prednisolone 
dose was increased to 3 mg/kg/day. On day 10 of 
prednisolone treatment, hemoglobin was 9.4 g/dL, 
direct Coombs immunoglobulin G (++), reticulocyte 
number was 10%, total bilirubin was 1.2 mg/dL and 
indirect bilirubin was 0.8 mg/dL, and the patient was 
discharged with a steroid decrement programme. 
Seven months later, the patient returned to the 
hospital with lassitude, paleness and weakness, and 
analyses revealed that hemoglobin: 4.7 g/dL, 
widespread schistocytes, spherocytes, polychromasia. 
Direct Coombs was 4+ positive and total bilirubin was 
5.4 mg/dL, direct bilirubin was 1.2 mg/dL, C3, C4, 
antinuclear antibody, anti-dsDNA and immunoglobulin 
levels were normal. The was accepted as relapse 
and steroid treatment (2 mg/kg/day) was started. 
Because the hemoglobin levels did not increase, the 
dose of steroid treatment is gradually increased to 6 
mg/kg/day. The hemoglobin level increased to 10.2 g/
dL. During the process of the gradual decrease of the 
steroid treatment, the hemoglobin levels decreased 
to 8.6 g/dL. Therefore, we treated the patient with 
the immunosuppressive drug Rituximab (375 mg/
m2/week) for 4 weeks. However, the remission did 
not occur. Along with the erythrocyte transfusion 
with intervals, treatment with mycophenolate 
motefil (MMF) was started with the two doses of 
15 mg/kg/day. Because of the failure assessing the 
remission, the dose of MMF was increased to 30 mg/
kg/day. On the day 21 of the treatment, the analyses 
revealed that WBC: 9.200 K/µL, hemoglobin: 10.6 g/
dL, thrombocyte counts: 422.000 K/µL, reticulocyte 
number: 8%, total bilirubin: 1.4 mg/dL, and the patient 
was discharged on the day 60. Hemoglobin levels on 
post-discharge day 30 was measured as 10.8 mg/dL. 
Measurement for hemoglobin was in remission on 
post-treatment month 4 and was measured as 13.6 
mg/dL, and is continued to be followed up.
Discussion
AIHA is a disease characterized by the 
degradation of the erythrocytes in the intravascular 
or reticuloendothelial system that is initiated by the 
immunoglobulin G and/or immunoglobulin M type 
of antibodies that bind to the surface antigens of 
the erythrocytes (1). Its etiology consists of collagen 
tissue diseases, lymphoproliferative diseases, non-
Hodgkin lymphoma, drugs (especially penicillins, 
cephalosporins etc.) and viral infections (2,3). In a 
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study including 285 children (age: 2.4-5.6) diagnosed 
with AIHA, 53% of the patients had immunological 
disorders, 37% of the patients were idiopathic and 
10% of the patients had infection (4). None of the 
factors were observed in our 2-year old patient. 
Autoantibodies are classified based on their types 
against the AIHA erythrocyte antigens. Our case is 
warm indirect haemagglutination that is characterized 
by the immunoglobulin G autoantibodies and is the 
most common type of the disease (4). Complaints 
such as anemia symptoms including weakness, 
fatigue, shortness of breath, dizziness and paleness, 
as well as jaundice and hematuria are observed (1). 
Those evidences are also present in our case. In 
laboratory evidences, normochromic and normocytic 
anemia, normalized number of reticulocytes formed 
by reticulocytosis, which the response of the bone 
marrow to the increased peripheral degradation, 
is >5% (2). In our case, reticulocyte number was 
17%. In peripheral smear, widespread schistocytes, 
polychromasia, spherocytes, as well as high serum 
levels of indirect bilirubin and LDH were observed in 
our case. Direct Coombs test positivity is a diagnostic 
test. It indicates the antibodies bound to the antigens 
on the erythrocyte surface. As the standard Coombs 
reactant anti-human immunoglobulin G causes 
agglutination in the presence of antibody and test 
gives (+) result (5). Response rate to the steroid 
treatment of the AIHA cases is 70-80% (2). However, 
abovementioned case is rare case because of the 
relapse and unresponsiveness to the steroid. Initial 
steroid dose 1-2 mg/kg/day and dose can be increased 
depending on the hemoglobin levels, as it was in our 
case (6). When the hemoglobin levels reach to the 
desired levels, dose is decreased slowly. Generally, 
the dose reaches down to 0.5 mg/kg/day within 4-6 
weeks. As it was in our case, the responsiveness to the 
treatment is checked regularly by the complete blood 
counts, reticulocyte counts and Coombs test. In the 
cases of either unresponsiveness within 4-6 weeks or 
not being in remission during the period of the steroid 
dose is decreased, alternative treatment options 
should be considered, as it was in our case. On the 
patients who are either unresponsive to the steroids 
or cannot tolerate, immunosuppressant treatment is 
also advised in order to continue the remission (3). 
In our case, our first-choice rituximab is an anti-CD 
20 monoclonal antibody and is used either in the 
resistant or glucocorticoid-dependent cases with the 
dose of 375 mg/m2/week for 4 weeks via intravenous 
infusion (7). In a study, responsiveness was found to 
be 50-60% (8). Side effects, such as fever, trembling, 
headache, dizziness, nausea, vomiting, hypotension 
and sinus tachycardia, can be observed in response 
to the rituximab treatment (9). However, we did 
not observe either any response or complications in 
response to the 4-week treatment in our case. Other 
immunosuppressive treatment choices include MMF, 
danazol, azathioprine and cyclosporine (1). In our 
case, we chose MMF as an immunomodulator after 
rituximab treatment. MMF can be applied with a 
dose of 2x30-40 mg/kg/day. In our case, we did not 
observe either any complications or side effects in 
response to the MMF, initial dose was 15 mg/kg/day, 
then escalated to 30 mg/kg/day. In previous studies, 
MMF treatment gives in successful results in the 
steroid-resistant AIHA, and in our study, patient was 
found to be in remission at 6-month post-treatment 
(10,11). In conclusion, AIHA is a type of anemia 
that successfully responds to the steroid treatment. 
However, it can continue with the relapses. When the 
steroid treatment is not responsive during relapses, 
there are various immunosuppressant treatment 
choices. MMF is one of the immunosuppressant drugs 
that we preferred in our case and obtained positive 
response.
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